Emsam Related Published Studies
Well-designed clinical trials related to Emsam (Selegiline Transdermal)
Efficacy of selegiline add on therapy to risperidone in the treatment of the negative symptoms of schizophrenia: a double-blind randomized placebo-controlled study. [2008.03]
A review of the literature on the selegiline transdermal system: an effective and well-tolerated monoamine oxidase inhibitor for the treatment of depression. [2008]
Selegiline transdermal system (STS) for HIV-associated cognitive impairment: open-label report of ACTG 5090. [2007.11]
Pharmacokinetics and absolute bioavailability of selegiline following treatment of healthy subjects with the selegiline transdermal system (6 mg/24 h): a comparison with oral selegiline capsules. [2007.10]
A multicenter trial of selegiline transdermal system for HIV-associated cognitive impairment. [2007.09.25]
Selegiline orally disintegrating tablets in patients with Parkinson disease and "wearing off" symptoms. [2007.09]
Safety and efficacy of newly formulated selegiline orally disintegrating tablets as an adjunct to levodopa in the management of 'off' episodes in patients with Parkinson's disease. [2007.04]
Selegiline Transdermal System: An Examination of the Potential for CYP450-Dependent Pharmacokinetic Interactions With 3 Psychotropic Medications. [2007.02]
Effects of a tyramine-enriched meal on blood pressure response in healthy male volunteers treated with selegiline transdermal system 6 mg/24 hour. [2007.01]
Treatment effects of selegiline transdermal system on symptoms of major depressive disorder: a meta-analysis of short-term, placebo-controlled, efficacy trials. [2007]
Double-blind, placebo-controlled trial of selegiline transdermal system (STS) for the treatment of cocaine dependence. [2006.12.01]
Selegiline transdermal system in the prevention of relapse of major depressive disorder: a 52-week, double-blind, placebo-substitution, parallel-group clinical trial. [2006.12]
Selegiline transdermal system for the treatment of major depressive disorder: an 8-week, double-blind, placebo-controlled, flexible-dose titration trial. [2006.09]
A randomized controlled trial of oral selegiline plus nicotine skin patch compared with placebo plus nicotine skin patch for smoking cessation. [2003.10]
A double-blind, placebo-controlled trial of the safety and efficacy of selegiline transdermal system without dietary restrictions in patients with major depressive disorder. [2003.02]
Transdermal selegiline in major depression: a double-blind, placebo-controlled, parallel-group study in outpatients. [2002.11]
Transdermal selegiline in HIV-associated cognitive impairment: pilot, placebo-controlled study. [2000.01.11]
Well-designed clinical trials possibly related to Emsam (Selegiline Transdermal)
Fourteen-year final report of the randomized PDRG-UK trial comparing three initial treatments in PD. [2008.08.12]
Monamine oxidase inhibitors: current and emerging agents for Parkinson disease. [2007.05]
Other research related to Emsam (Selegiline Transdermal)
Synergistic effects of selegiline and donepezil on cognitive impairment induced by amyloid beta (25-35). [2008.07.19]
Comparison of neuroprotective and neurorestorative capabilities of rasagiline and selegiline against lactacystin-induced nigrostriatal dopaminergic degeneration. [2008.06]
Selegiline reduces cisplatin-induced neuronal death in neuroblastoma cells. [2008.05]
The selegiline transdermal system in major depressive disorder: A systematic review of safety and tolerability. [2008.01]
Differential behavioral syndrome evoked in the rats after multiple doses of SSRI fluoxetine with selective MAO inhibitors rasagiline or selegiline. [2008]
Symptoms of sexual dysfunction in patients treated for major depressive disorder: a meta-analysis comparing selegiline transdermal system and placebo using a patient-rated scale. [2007.12]
Zydis selegiline in the management of Parkinson's disease. [2007.10]
Selegiline transdermal system: current awareness and promise. [2007.08.15]
Evaluation of the potential for pharmacodynamic and pharmacokinetic drug interactions between selegiline transdermal system and two sympathomimetic agents (pseudoephedrine and phenylpropanolamine) in healthy volunteers. [2007.08]
The selegiline transdermal system in major depressive disorder: A systematic review of safety and tolerability. [2007.06.11]
Transdermal selegiline. [2007.06]
The role of selegiline in the treatment of negative symptoms associated with schizophrenia. [2007.05]
Selegiline and blood pressure in patients with Parkinson's disease. [2007.02]
Selegiline transdermal system: in the treatment of major depressive disorder. [2007]
Tyramine pressor sensitivity during treatment with the selegiline transdermal system 6 mg/24 h in healthy subjects. [2006.08]
Transdermal selegiline: the new generation of monoamine oxidase inhibitors. [2006.05]
Effect of nerodilol, carvone and anethole on the in vitro transdermal delivery of selegiline hydrochloride. [2006.01]
Transdermal selegiline and intravenous cocaine: safety and interactions. [2004.02]
Daily transdermal administration of selegiline to guinea-pigs preferentially inhibits monoamine oxidase activity in brain when compared with intestinal and hepatic tissues. [2003.01]
Selegiline transdermal system Somerset. [2002.08]
Oral versus transdermal selegiline: antidepressant-like activity in rats. [1999.07]
Integrated pharmacokinetic and metabolic modeling of selegiline and metabolites after transdermal administration. [1997.10]
Clinical pharmacokinetics and pharmacodynamics of selegiline. An update. [1997.08]
Pressor response to tyramine after single 24-hour application of a selegiline transdermal system in healthy males. [1997.03]
Other possibly related research studies
Translating the evidence on atypical depression into clinical practice. [2007.04]
Translating the evidence on atypical depression into clinical practice. [2007]
Bipolar depression: a review of randomised clinical trials. [2007.01]
Advances in the treatment of depression. [2006.01]
Pharmacokinetic optimisation in the treatment of Parkinson's disease : an update. [2006]
Alternatives to levodopa in the initial treatment of early Parkinson's disease. [2005]
Combining stimulants with monoamine oxidase inhibitors: a review of uses and one possible additional indication. [2004.11]
Gateways to clinical trials. [2004.01]
Gateways to clinical trials. March 2003. [2003.03]
Gateways to Clinical Trials. [2002.09]
Fourteen-year final report of the randomized PDRG-UK trial comparing three initial treatments in PD. [2008.06.25]
Effect of MAO-B inhibition against ischemia-induced oxidative stress in the rat brain. Comparison with a rational antioxidant. [2008]
The effects of antidepressants in Parkinson's disease: a meta-analysis. [2008.05]
Protection against Parkinson's disease progression: clinical experience. [2008.04]
Treatment options in Alzheimer's disease: maximizing benefit, managing expectations. [2008]
[The use of Stalevo in Hungary for patients with Parkinson disease and its effect on the quality of life] [2008.01.30]
The PPARgamma agonist pioglitazone is effective in the MPTP mouse model of Parkinson's disease through inhibition of monoamine oxidase B. [2008.05]
[Low dose pergolide induced systemic edema and pleural effusion in a patient with Parkinson's disease] [2008.02]
[Role of apoptosis in the kidney after reperfusion] [2008.02.17]
Practice parameters for the treatment of narcolepsy and other hypersomnias of central origin. [2007.12.01]
Predictors of deterioration in health-related quality of life in Parkinson's disease: results from the DATATOP trial. [2008.04.15]
Monoamine oxidase-B inhibition in the treatment of Parkinson's disease. [2007.12]
Biomarkers, laboratory, and animal models for the design and development of adjunctive therapies for HIV-1 dementia and other neuroinflammatory disorders. [2007.03]
Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's Disease. [2007.09]
Pharmacokinetic studies of (-)-deprenyl and some of its metabolites in mouse. [2007]
Community and long-term care management of Parkinson's disease in the elderly: focus on monoamine oxidase type B inhibitors. [2007]
Gestational exposure to nicotine and monoamine oxidase inhibitors influences cocaine-induced locomotion in adolescent rats. [2007.11]
Deprenyl treatment attenuates long-term pre- and post-synaptic changes evoked by chronic methamphetamine. [2007.11.14]
Medical management of levodopa-associated motor complications in patients with Parkinson's disease. [2007]
A beam-walking apparatus to assess behavioural impairments in MPTP-treated mice: pharmacological validation with R-(-)-deprenyl. [2007.08.15]
Therapeutic advances in narcolepsy. [2007.06]
The effect of l-deprenyl on tissue mRNA expressions of NOS isoforms and NO levels in an experimental diabetes mellitus model. [2007]
Low plasma uric acid level in Parkinson's disease. [2007.06.15]
The kinetics of inhibition of human acetylcholinesterase and butyrylcholinesterase by two series of novel carbamates. [2007.06]
Management of sexual dysfunction due to antipsychotic drug therapy. [2007.01.24]
Bacopa monniera prevents from aluminium neurotoxicity in the cerebral cortex of rat brain. [2007.04.20]
Chronic (-)-deprenyl administration attenuates dendritic developmental impairment induced by early social isolation in the rat. [2007]
Long-term outcome in Parkinson disease: no advantage to initiating therapy with dopamine agonists. [2008.10.14]
[Motor symptoms in Parkinson disease] [2008.09.25]
Rasagiline in treatment of Parkinson's disease. [2008.02]
|
